Biotechnology Assets Stock

Biotechnology Assets EBIT

The EBIT of Biotechnology Assets (BST.MC) as of Jul 22, 2026 is -2.00 M EUR. In the previous year, EBIT was 3.35 M EUR — a change of -159.86% (lower).

EBIT

-2.00 MEUR

YoY

-159.86%

Last updated:

In 2026, Biotechnology Assets's EBIT was -2.00 M EUR, a -159.86% increase from the 3.35 M EUR EBIT recorded in the previous year.

The Biotechnology Assets EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M EUR)
Date
EBIT (M EUR)
Jan 1, 2017
-0.26 base
Jan 1, 2018
-14.41 base
Jan 1, 2019
-1.88 base
Jan 1, 2020
-0.57 base
Jan 1, 2021
-1.42 base
Jan 1, 2022
-1.09 base
Jan 1, 2023
3.35 base
Jan 1, 2024
-2.00 base
YEAREBIT (M EUR)
2024 -2.00
2023 3.35
2022 -1.09
2021 -1.42
2020 -0.57
2019 -1.88
2018 -14.41
2017 -0.26
2016 -1.67
2015 -0.59
2014 0.33
2013 0.22
2012 -0.76
2011 -0.08
2010 -0.06
Access this data via the Eulerpool API

Biotechnology Assets Revenue

Biotechnology Assets Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2017
2.39 M EUR
-260,000.00 EUR
-70,000.00 EUR
Jan 1, 2018
23.32 M EUR
-14.41 M EUR
-16.98 M EUR
Jan 1, 2019
2.13 M EUR
-1.88 M EUR
-10.08 M EUR
Jan 1, 2020
2.52 M EUR
-570,000.00 EUR
-8.61 M EUR
Jan 1, 2021
3.09 M EUR
-1.42 M EUR
-3.01 M EUR
Jan 1, 2022
2.61 M EUR
-1.09 M EUR
-1.94 M EUR
Jan 1, 2023
3.60 M EUR
3.35 M EUR
1.57 M EUR
Jan 1, 2024
2.51 M EUR
-2.00 M EUR
-2.92 M EUR

Biotechnology Assets Margins

Biotechnology Assets stock margins

The Biotechnology Assets margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biotechnology Assets. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biotechnology Assets.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2017
137.24 %
-10.88 %
-2.93 %
Jan 1, 2018
1.42 %
-61.79 %
-72.81 %
Jan 1, 2019
77.00 %
-88.26 %
-473.24 %
Jan 1, 2020
83.73 %
-22.62 %
-341.67 %
Jan 1, 2021
48.22 %
-45.95 %
-97.41 %
Jan 1, 2022
67.05 %
-41.76 %
-74.33 %
Jan 1, 2023
68.45 %
92.90 %
43.70 %
Jan 1, 2024
76.12 %
-79.64 %
-116.01 %

Biotechnology Assets Stock analysis

What does Biotechnology Assets do? ADL Bionatur Solutions SA is a Swiss company specializing in the development and production of natural ingredients for the food, cosmetics, and pharmaceutical industries. The company was founded in 2000 and has since had an impressive success story. ADL Bionatur Solutions SA's business model is based on the use of plants and microorganisms to extract high-quality natural active ingredients. The company employs environmentally friendly methods and sustainable production practices that meet the needs of society and nature alike. One of ADL Bionatur Solutions SA's main sectors is the production of natural flavors and colorants for the food industry. Depending on customer preferences, color pigments are extracted from fruits, vegetables, or other plants to color food products with natural ingredients. Natural flavors are also isolated using plant extracts and other natural sources. These products are particularly sought after because they are not only healthier than synthetic alternatives but also provide consumers with a better feeling. Another significant sector of ADL Bionatur Solutions SA is the development of cosmetics based on natural ingredients. For example, extracts from algae, flowers, or herbs are used to create skincare products that are gentle on the skin while still being highly effective. Products targeting signs of aging or acne are also based on natural ingredients from ADL Bionatur Solutions SA. In addition to these two main sectors, ADL Bionatur Solutions SA also offers products for the pharmaceutical industry. The company focuses on developing active ingredients based on natural substances that can be used to treat various diseases. Sustainability is also a key focus here, as naturally derived active ingredients are not only healthier but also have a higher biological availability. In addition to these main sectors, ADL Bionatur Solutions SA provides consulting services to customers. This includes the development of tailored natural solutions and support for product certification according to the highest international standards. Overall, in recent years, ADL Bionatur Solutions SA has become one of the world's leading companies in the field of natural ingredients. With a wide portfolio of products and services and a strong focus on sustainability and environmental compatibility, the company is well-positioned to benefit from the ongoing trend towards natural and healthier products. Biotechnology Assets is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Biotechnology Assets's EBIT

Biotechnology Assets's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Biotechnology Assets's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Biotechnology Assets's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Biotechnology Assets’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Biotechnology Assets stock

EBIT of Biotechnology Assets is -2.00 M EUR in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Biotechnology Assets

All Key Metrics — Biotechnology Assets